What is Elephas?
Elephas develops a sophisticated oncology platform designed to predict patient response to immunotherapy. Leveraging live tissue from biopsies, the company's technology measures immunotherapy response within 72 hours. This rapid assessment preserves the native tumor microenvironment, capturing the intricate interplay of genes, proteins, tumor cells, stroma, and immune cells. The platform's tumor-agnostic design allows for evaluation across multiple cancer indications and immunotherapy types, empowering oncologists and pharmaceutical companies to forecast clinical treatment outcomes prior to initiation and to expedite drug development pipelines.
How much funding has Elephas raised?
Elephas has raised a total of $136.5M across 3 funding rounds:
Series B
$41.5M
Series C
$55M
Other Financing Round
$40M
Series B (2022): $41.5M, investors not publicly disclosed
Series C (2024): $55M led by State of Wisconsin - Investment Board, Sands Capital, Northpond Ventures, and Arch Ventures
Other Financing Round (2025): $40M supported by ARCH VENTURE PARTNERS, Sands Capital, Tao Capital Management, and Northpond Ventures
Key Investors in Elephas
ARCH VENTURE PARTNERS
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Sands Capital
Established in 1992, Sands Capital Management is headquartered in Arlington, Virginia. They manage equity mutual funds, invest in public equity markets, and more.
Northpond Ventures
Northpond Ventures is dedicated to advancing science and technology to create significant impacts on humanity. The company focuses on identifying and supporting breakthrough innovations and entrepreneurial ventures. Their portfolio includes various companies that have been acquired by major industry players, indicating a strong commitment to fostering scientific advancements. Northpond Ventures aims to partner with innovators and visionaries to drive meaningful change in the scientific landscape.
What's next for Elephas?
With substantial enterprise-level backing and a recent major strategic investment, Elephas is well-positioned for accelerated growth and market penetration. The company's ability to accurately predict immunotherapy response is a critical advancement in personalized oncology, potentially transforming treatment strategies and reducing the time and cost associated with drug development. Future endeavors will likely focus on expanding the platform's clinical validation, forging strategic partnerships with pharmaceutical giants, and scaling its commercial operations to meet the growing demand for precise, predictive cancer diagnostics. The consistent flow of significant capital indicates a strong market belief in Elephas's technology and its potential to significantly impact cancer care.
See full Elephas company page
